Ai. Ernst et al., Ectopic expression of human topoisomerase II alpha fragments and etoposideresistance in mammalian cells, INT J CANC, 88(1), 2000, pp. 99-107
Cellular resistance to etoposide has been correlated both with reduced leve
ls and an aberrant cytoplasmic accumulation of the drug's target, topoisome
rase 11 alpha (topo 11 alpha), It is not known, however, whether a cytoplas
mic pool of topo 11 alpha is sufficient to confer drug resistance on cultur
ed mammalian cells. In our study, we have transfected mouse fibroblasts and
human 293 cells with truncated forms of human topo 11 alpha fused to GFP a
nd have examined the transformants for the subcellular localization of topo
II alpha and their resistance to etoposide. Transient transfection resulte
d in high-level expression of all GFP-topo II alpha fusions tested, whereas
in stably transfected cells the levels varied significantly, Transfectants
expressing a central or a carboxy-terminal topo II alpha domain (aa 428-15
04, 639-1028 or 1028-1504) accumulated high levels of the fusion proteins,
while only very low amounts of GFP-topo 11 alpha proteins were observed in
cell lines expressing constructs that retain the amino-terminus of the enzy
me (aa 1-1214, aa 1-939, aa 1-611). Our results suggest that the topo II al
pha amino-terminus affects the stability of truncated forms of the enzyme i
n mammalian cells, perhaps due to targeted degradation. Assays that screen
for cell vitality and DNA synthesis reveal no significant changes in etopos
ide sensitivity in transfected cells expressing high levels of cytoplasmic
or nuclear localized topo ii fusion proteins. Retroviral expression of a cy
toplasmically anchored domain of human topo II alpha also failed to confer
drug resistance. These results suggest that a cytoplasmic pool of topo II a
lpha is not sufficient to render cultured mammalian cells drug resistant. (
C) 2000 Wiley-Liss, Inc.